You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CLINICAL TRIALS PROFILE FOR COPPER CU-64 DOTATATE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for copper cu-64 dotatate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT04234568 ↗ Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors Recruiting National Cancer Institute (NCI) Phase 1 2020-06-29 This phase I trial studies the side effects and best dose of triapine when given together with lutetium Lu 177 dotatate in treating patients with neuroendocrine tumors. Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radioactive drugs, such as lutetium Lu 177 dotatate, may carry radiation directly to tumor cells and not harm normal cells. Giving triapine and lutetium Lu 177 dotatate together may be a good way in treating patients with neuroendocrine tumors.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for copper cu-64 dotatate

Condition Name

Condition Name for copper cu-64 dotatate
Intervention Trials
Digestive System Neuroendocrine Tumor 1
Metastatic Well Differentiated Neuroendocrine Neoplasm 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for copper cu-64 dotatate
Intervention Trials
Neuroendocrine Tumors 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for copper cu-64 dotatate

Trials by Country

Trials by Country for copper cu-64 dotatate
Location Trials
United States 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for copper cu-64 dotatate
Location Trials
Utah 1
Pennsylvania 1
Ohio 1
Minnesota 1
Massachusetts 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for copper cu-64 dotatate

Clinical Trial Phase

Clinical Trial Phase for copper cu-64 dotatate
Clinical Trial Phase Trials
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for copper cu-64 dotatate
Clinical Trial Phase Trials
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for copper cu-64 dotatate

Sponsor Name

Sponsor Name for copper cu-64 dotatate
Sponsor Trials
National Cancer Institute (NCI) 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for copper cu-64 dotatate
Sponsor Trials
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.